These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34217975)

  • 1. Rational design of phenyl thiophene (pyridine) derivatives that overcome P-glycoprotein mediated MDR in MCF-7/ADR cell.
    Li YS; Mao S; Zhao DS; Wang CC; Zu D; Yang X; Liu GJ; Wang SJ; Zhang B; Bao XZ; Ye XY; Wei B; Cui ZN; Chen JW; Wang H
    Bioorg Chem; 2021 Sep; 114():105075. PubMed ID: 34217975
    [No Abstract]   [Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamide derivatives as novel P-glycoprotein inhibitors reversing multidrug resistance.
    Qiu Q; Zhou J; Shi W; Kairuki M; Huang W; Qian H
    Bioorg Chem; 2019 May; 86():166-175. PubMed ID: 30710850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
    Li YS; Yang X; Zhao DS; Cai Y; Huang Z; Wu R; Wang SJ; Liu GJ; Wang J; Bao XZ; Ye XY; Wei B; Cui ZN; Wang H
    Eur J Med Chem; 2021 Apr; 216():113336. PubMed ID: 33725657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of chalcones as reversers of P-glycoprotein-mediated multidrug resistance.
    Yin H; Dong J; Cai Y; Shi X; Wang H; Liu G; Tang Y; Liu J; Ma L
    Eur J Med Chem; 2019 Oct; 180():350-366. PubMed ID: 31325783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells.
    Kairuki M; Qiu Q; Pan M; Li Q; Zhou J; Ghaleb H; Huang W; Qian H; Jiang C
    Bioorg Med Chem; 2019 Aug; 27(15):3347-3357. PubMed ID: 31202598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.
    Kobayashi E; Iyer AK; Hornicek FJ; Amiji MM; Duan Z
    Clin Orthop Relat Res; 2013 Mar; 471(3):915-25. PubMed ID: 23011844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein.
    Zhang FY; Du GJ; Zhang L; Zhang CL; Lu WL; Liang W
    Pharm Res; 2009 Apr; 26(4):914-25. PubMed ID: 19067124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition.
    Rouibah H; Kebsa W; Lahouel M; Zihlif M; Ahram M; Aburmeleih B; Mustafa E; Al-Ameer HJ
    Anticancer Agents Med Chem; 2018; 18(3):375-387. PubMed ID: 29318976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 2-(alkoxycarbonyl)-3-anilinobenzo[b]thiophenes and thieno[2,3-b]pyridines as new potent anticancer agents.
    Romagnoli R; Baraldi PG; Kimatrai Salvador M; Preti D; Aghazadeh Tabrizi M; Bassetto M; Brancale A; Hamel E; Castagliuolo I; Bortolozzi R; Basso G; Viola G
    J Med Chem; 2013 Mar; 56(6):2606-18. PubMed ID: 23445496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-benzazecine-based cyclic allene derivatives as highly potent P-glycoprotein inhibitors overcoming doxorubicin multidrug resistance.
    Titov AA; Niso M; Candia M; Kobzev MS; Varlamov AV; Borisova TN; Voskressensky LG; Colabufo NA; Cellamare S; Pisani L; Altomare CD
    Future Med Chem; 2019 Aug; 11(16):2095-2106. PubMed ID: 31538529
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
    Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
    Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
    Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
    Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and cytotoxicity of thieno[2,3-b]pyridine and furo[2,3-b]pyridine derivatives.
    Hung JM; Arabshahi HJ; Leung E; Reynisson J; Barker D
    Eur J Med Chem; 2014 Oct; 86():420-37. PubMed ID: 25194934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
    Li C; Guan X; Xue H; Wang P; Wang M; Gai X
    Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A self-assembled pH/enzyme dual-responsive prodrug with PEG deshielding for multidrug-resistant tumor therapy.
    Ni R; Zhu J; Xu Z; Chen Y
    J Mater Chem B; 2020 Feb; 8(6):1290-1301. PubMed ID: 31967176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
    Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
    Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance.
    Yu J; Chen H; Jiang L; Wang J; Dai J; Wang J
    J Pharm Sci; 2019 May; 108(5):1788-1799. PubMed ID: 30610857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells.
    Zhu CY; Lv YP; Yan DF; Gao FL
    Asian Pac J Cancer Prev; 2013; 14(11):6757-60. PubMed ID: 24377601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle.
    Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ
    Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.